336 related articles for article (PubMed ID: 32343424)
21. Voxelotor use in adults with sickle cell disease in a real-world setting.
Curtis SA; Betancourt J; Kottapalli N; Campbell S; Minniti C
Am J Hematol; 2022 Mar; 97(3):E125-E128. PubMed ID: 34967959
[No Abstract] [Full Text] [Related]
22. Patient perception of voxelotor treatment benefit in sickle cell disease.
Idowu M; Haque A; Williams EM; Sridhar A
J Investig Med; 2022 Jun; 70(5):1316-1319. PubMed ID: 35732337
[TBL] [Abstract][Full Text] [Related]
23. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
Ferlis M; Lipato T; Roseff SD; Smith WR
Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials.
Tanriverdi LH; Sarici A; Erkurt MA; Parlakpinar H
Int J Clin Pract; 2021 Jun; 75(6):e13967. PubMed ID: 33369007
[TBL] [Abstract][Full Text] [Related]
25. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
26. Accelerated approval of Oxbryta® (voxelotor): A case study on novel endpoint selection in sickle cell disease.
Lehrer-Graiwer J; Yokoshima L; Tong B; Love TW
Contemp Clin Trials; 2020 Nov; 98():106161. PubMed ID: 33010428
[TBL] [Abstract][Full Text] [Related]
27. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
[No Abstract] [Full Text] [Related]
28. Blocking HbS Polymerization in SCD.
Lettre G
Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
[TBL] [Abstract][Full Text] [Related]
29. Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma.
Savic RM; Green ML; Jorga K; Zager M; Washington CB
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):687-697. PubMed ID: 35447014
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease.
Weaver SB; Akinwale H; Nonyel NP; Wingate LT
Expert Rev Hematol; 2024 Jun; 17(6):255-260. PubMed ID: 38753522
[TBL] [Abstract][Full Text] [Related]
31. Voxelotor treatment of a patient with sickle cell disease and very severe anemia.
Shet AS; Mendelsohn L; Harper J; Ostrowski D; Henry ER; Gwaabe E; Nichols J; Alayash AI; Eaton WA; Thein SL
Am J Hematol; 2019 Apr; 94(4):E88-E90. PubMed ID: 30592074
[No Abstract] [Full Text] [Related]
32. Doping control approach: Identification of equine in vitro metabolites of voxelotor (GBT440), a hemoglobin S polymerization inhibitor.
Subhahar MB; Karakka Kal AK; Philip M; Muhammed Ajeebsanu M; Karatt TK; Perwad Z
Rapid Commun Mass Spectrom; 2024 Jan; 38(2):e9671. PubMed ID: 38124165
[TBL] [Abstract][Full Text] [Related]
33. The influence of voxelotor on cerebral blood flow and oxygen extraction in pediatric sickle cell disease.
Brothers RO; Turrentine KB; Akbar M; Triplett S; Zhao H; Urner TM; Goldman-Yassen A; Jones RA; Knight-Scott J; Milla SS; Bai S; Tang A; Brown RC; Buckley EM
Blood; 2024 May; 143(21):2145-2151. PubMed ID: 38364110
[TBL] [Abstract][Full Text] [Related]
34. Real-world data on voxelotor to treat patients with sickle cell disease.
Muschick K; Fuqua T; Stoker-Postier C; Anderson AR
Eur J Haematol; 2022 Aug; 109(2):154-161. PubMed ID: 35460521
[TBL] [Abstract][Full Text] [Related]
35. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
[TBL] [Abstract][Full Text] [Related]
36. Hb S (
Tsitsikas DA; Kamal M; Braimoh A; Benson S; Abukar J
Hemoglobin; 2021 Nov; 45(6):355-357. PubMed ID: 33622152
[TBL] [Abstract][Full Text] [Related]
37. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis.
Shah N; Lipato T; Alvarez O; Delea T; Lonshteyn A; Weycker D; Nguyen A; Beaubrun A; Agodoa I
Expert Rev Hematol; 2022 Feb; 15(2):167-173. PubMed ID: 35191358
[TBL] [Abstract][Full Text] [Related]
38. Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study.
Brown C; Idowu M; Drachtman R; Beaubrun A; Agodoa I; Nguyen A; Lipman K; Moshkovich O; Murphy R; Bellenger MA; Smith W
Biomed Res Int; 2023; 2023():7533111. PubMed ID: 36748060
[TBL] [Abstract][Full Text] [Related]
39. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
40. Unique Hemoglobinopathy Pattern Following Treatment with Voxelotor.
Poventud-Fuentes I; Portillo TP; Olayinka L; Marcogliese AN; Tubman VN; Devaraj S
Ann Clin Lab Sci; 2023 Jul; 53(4):647-652. PubMed ID: 37625829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
